Harbin Pharmaceutical Group
Harbin Pharma is a pharmaceuticals company based out of Harbin.
Launch date
Employees
Market cap
€951m
Enterprise valuation
€810m (Public information from Sep 2024)
Share price
CNY3.04 600664.SS
Harbin Heilongjiang (HQ)
Financials
Estimates*
| CNY | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 11.8b | 10.8b | 12.8b | 13.8b | 15.5b | 138.8b |
| % growth | - | - | (9 %) | 19 % | 8 % | 12 % | - |
| EBITDA | - | 1.0b | (29.4m) | 898m | 1.0b | 1.1b | - |
| % EBITDA margin | - | 8 % | - | 7 % | 7 % | 7 % | - |
| Profit | - | 55.8m | (1.1b) | 371m | 464m | 395m | - |
| % profit margin | - | - | (10 %) | 3 % | 3 % | 3 % | - |
| EV / revenue | - | 0.8x | 0.8x | 0.8x | 0.5x | 0.5x | - |
| EV / EBITDA | - | 9.5x | -301.7x | 10.8x | 7.1x | 6.7x | - |
| R&D budget | - | 125m | 92.5m | 97.7m | 116m | 106m | - |
| R&D % of revenue | - | 1 % | 1 % | 1 % | 1 % | 1 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | N/A | IPO | |
| N/A | N/A | Growth Equity VC | |
| Total Funding | - | ||
